ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

Sinovac booster insufficient against omicron, study shows

China COVID vaccine fails to produce enough antibodies: Hong Kong universities

A healthcare worker and Sinovac vaccine recipient in Jakarta, Indonesia, on Dec. 14. Sinovac says that 94% of those who receive three doses of its vaccine generate enough neutralizing antibodies to protect against the omicron variant.   © Reuters

HONG KONG -- A third dose of Sinovac's COVID vaccine does not provide sufficient protection against the omicron variant, new research reveals, contradicting the Chinese vaccine maker's pronouncement that it does.

The University of Hong Kong (HKU) and Chinese University of Hong Kong conducted the study, finding that a third shot of what is one of the world's most widely used COVID vaccines does not produce enough levels of virus-neutralizing antibodies. A third dose of a vaccine produced by Pfizer and BioNTech, however, significantly improved protection for those who had previously taken two doses of Sinovac, also known as CoronaVac, the research shows.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more